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Abstract 
 
Background: To compare the effect of vaginal 
isosorbide mononitrate with misoprostol for cervical 
ripening in women with first trimester missed abortion 
before surgical evacuation of uterus. 
Methods: In this randomized controlled trial, hundred 
patients, requiring cervical ripening and surgical 
evacuation of retained products of conception,  were 
divided into two equal groups. Misoprostol (400 
microgram) was placed in posterior vaginal fornix in 
Group A patients and dose was repeated every three hours 
upto 4 doses or until reaching cervical ripening.  
Isosorbide mononitrate (80milligram) was given vaginally 
in Group B patients and dose was repeated every three 
hours up to 4 doses or until reaching the cervical ripening.  
Results: There was no significant difference in side 
effects between two groups. However Misoprostol was 
more effective than Isosorbide Mononitrate (IMN) to cause 
cervical ripening before suction termination of first 
trimester missed abortion . 
Conclusion: Nitric oxide donor “Isosorbide 
mononitrate” is less effective than “Misoprostol” to induce 
cervical ripening prior to first trimester surgical evacuation 
of retained products of conception and both drugs are 
associated with a high frequency of side effects. 
Key Words: Cervical Ripening, Missed abortion, nitric 
oxide donor, misoprostol. 
 
Introduction 
 
The uterine cervix has to be firm enough to 
retain the conceptus through the pregnancy and on the 
other hand have the ability to soften before and during 
labour to enable the birth of infant.  Cervical ripening 
and maturation is very important pre-requisite for the 
successful termination of pregnancy.1  
Two major techniques for iatrogenic cervical 
ripening are mechanical intervention such as 
disruption of fetal membranes or insertion of dilators 
and application of cervical ripening agent such as 
prostaglandin.2 However prostaglandins are 
associated with side effects such as   nausea, vomiting, 
diarrhoea, abdominal cramps, chills, shivering and 
uterine hyperstimulation.3 
Nitric oxide releasing drugs are the novel class 
of effective and safe drugs for cervical ripening.4,5 It 
has been shown to be a major paracrine mediator of 
numerous biological processes including smooth 
muscle relaxation, host defence and inflammation. 6 
Cervical ripening is thus associated with changes in 
local cytokines, prostaglandins and metalloproteases 
as well as in other bioregulators that play role in 
inflammation and in collagen metabolism.7 These 
factors also take part in regulation of nitric oxide 
synthesis and release. 8  Several chemical donors of 
nitric oxide are currently being used in various types 
of experimental and therapeutic studies. 9 
 
Patients and Methods 
 
In this randomized controlled trial, all patients 
admitted through OPD and emergency of Gynae / 
Obstetrics  unit of DHQ Teaching hospital, having 
ultrasound evidence of a gestation sac and a non-
viable embryo requiring cervical ripening and surgical 
evacuation of retained products of conception, were 
included. Women with unexplained vaginal bleeding 
or discharge, with any contraindication to use of 
isosorbide mononitrate, cardiac disease or 
hypersensitivity to the drug and cervical dilatation 
more than 8mm were excluded from study. Vaginal 
examination was carried out at the time of admission 
to assess cervical ripening 
Randomization was done (lottery method) and 
double blind technique was applied to decrease 
observer bias and patient bias.In group A patient’s  
400 micro gram of misoprostol was placed in posterior 
vaginal fornix every 3 hrs up to four doses or until 
reaching cervical ripening. The maximum dose of 
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misoprostol was 1600 microgram. In group B patient’s 
80mg of isosorbide mononiterate was given vaginally 
and dose was repeated every three hrs up to four 
doses or until reaching cervical ripening. The 
maximum dose of isosorbide mononitrate was 320mg.  
During this procedure vital signs, symptoms 
and adverse effects were recorded at base line and 
then every 3 hrs until finishing therapy.  Time of 1st, 
2nd, 3rd and 4th dose of tablet was noted and 
induction – ripening interval was recorded. If cervical 
dilatation was more than or equal to 8mm, then 
surgical evacuation of retained products of conception 
was performed. 
Mean and standard deviations were calculated 
for quantitative variables i.e. induction-ripening 
interval, age, parity, duration of gestation and cervical 
score. Frequencies and percentages were calculated for 
qualitative variables such as headache, abdominal 
pain, pelvic pain, backache, nausea and vomiting. 
Independent sample t-test was used to compare 
induction-ripening interval between isosorbide 
mononitrate and misoprostol. Chi-square test was 
used to compare the side effects.. P value less than 0.05 
was taken as significant.   
 
Results 
 
In isosorbide mononitrate (IMN) group the 
mean age was 27.52 ±5.168 years ranging from 18 to 40 
years and in Misoprostol group the mean age was 
28.26±5.244 years. The gestational age in both groups 
was almost same .The parity distribution showed that 
in IMN group 28% were primipara 52% were multi 
para and 20% were grand multi para. In Misoprostol 
group 10% were primipara, 82% were multipara and 
8% were grand multipara.  
Both the drugs were used as until the 
ripening, the frequency of doses was relatively higher 
in IMN group. The highest dose frequency that was 
used in Misoprostol group was 1. In 29 patients the 
required level was achieved after 1 dose of 
Misoprostol but in the IMN group the highest 
frequency of doses used was 2 doses which were used 
in 19 patients followed by 4 doses which were used in 
17 patients as given in (Table 1).  
In Misoprostol group the interval with highest 
frequency was 3 hours at which 30 (59%) patients 
achieved the required level. This interval was 
comparatively higher in IMN group in which the 
interval at which the required level was achieved was 
6 hours (32%), followed by 9 hours (26%) as given in 
Table 2.  The analysis of data showed that the mean 
induction to ripening interval was significantly 
(8.03±2.833 vs. 4.47±2.042, P-value < 0.05) higher in 
IMN group as compared with Misoprostol group, 
which is shown in Table 3. 
 
Table 1:Distribution of Doses in both Groups 
No. Of Doses 
Drug Group 
Total 
IMN Misoprostol 
 
1 6 29 35 
2 19 7 26 
3 8 11 19 
4 17 3 20 
Total 50 50 100 
 
Table 2: Induction to ripening interval 
Drug Group 
Induction to 
ripening 
interval 
Frequency Percent 
Misoprostol No Effect 3 6.0 
  3 29 58.0 
  6 13 26.0 
  9 5 10.0 
  12 0 0 
 Total 50 100.0 
IMN No Effect 8 16.0 
  3 4 8.0 
  6 16 32.0 
  9 13 26.0 
  12 9 18.0 
  Total 50 100.0 
 
Table 3:Comparison of Induction to 
Ripening Interval (hours) 
Drug Group Mean Std. Deviation P-value 
IMN 8.03 2.833 
0.000 
Misoprostol 4.47 2.042 
 
In side effects profile headache was 
significantly high in IMN group than Misoprostol 
group (p-value 0.05). There was no significant 
difference in hypotension in both groups (p-value 
<0.05). Abdominal pain was significantly higher in 
Misoprostol group as compared to IMN group (p-
value<0.05) .The backache was same in both groups 
(p-value>0.05). The nausea was only observed in 
Misoprostol group (p-value <0.05) that was 
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significantly higher as compared to IMN group. The 
results also show that vomiting was higher in 
Misoprostol group as compared to IMN group (Table 
4). 
Table 4:Comparison of side effects  
Side Effects Misoprostol IMN P-Value 
Headache 06 30 0.00 
Hypotension 00 2 0.153* 
Abdominal Pain 06 1 0.05* 
Backache 5 5 1.00* 
Nausea 8 0 0.003 
Vomiting  4 0 0.041* 
 
Discussion 
 
The present study showed that misoprostol 
(400 microgram) induced a more rapid cervical 
dilatation as compared to Isosorbide mononitrate 
(80mg). The induction - ripening interval was 
significantly higher in IMN group as compared to 
Misoprostol group. In Misoprostol group the interval 
with highest frequency was 3 hours at which 29(58%) 
patients achieved required level. This interval was 
comparatively higher in IMN group in which the 
interval at which required level was achieved was 6 
hours (32%) followed by 9 hours (26%). Similarly the 
frequency of doses was relatively higher in IMN 
group. The highest dose frequency, which was used in 
Misoprostol group, was 1 in 29 patients while in IMN 
group the highest dose frequency was 2 doses, which 
were used in 19 patients followed by 4 doses, which 
were used in 17 patients. The poor clinical response of 
IMN in above-mentioned study and in our study is 
difficult to explain. It is unlikely that dosage of IMN 
has any major effect as a higher dose of IMN (80mg) 
gave the same ripening effects as 40mg of IMN. 
The side effects were more frequently seen in 
our study which may be due to the fact that we used 
maximum 4 doses of each drug in our patients where 
as in studies with less side effects single dose of each 
drug was used. Another study was published in 2008 
on the side effects of vaginal application of IMN, 
Misoprostol and DILAPAN-S, a hygroscopic cervical 
dilator prior to first trimester curettage. This study 
showed that all patients indicated mild discomfort 
after DILAPAN where as no patient complained of 
discomfort after Misoprostol or IMN (P<. 0001). 3 
patients suffered from mild hypotension and headache 
after IMN and 2 had increased vaginal bleeding due to 
uterine atony during surgery (p<0.05). In this study 
80mg of IMN and 200microgram of Misoprostol 
vaginal gel was used to cause cervical ripening. 10  
Conclusion 
 
1. Benefits of Misoprostol are greater than its side 
effects so it is a better cervical ripening agent prior to 
suction evacuation of first trimester missed abortion 
with acceptable side effects. 
2. Use of Misoprostol for cervical ripening reduces the 
induction to ripening interval leading to early  surgical 
evacuation and short hospital stay. 
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